Since the declaration of COVID-19 by WHO as a pandemic on March 11, 2020, the outbreak is adversely impacting numerous individuals worldwide. Due to the low availability of test kits and sensitivity/specificity issues associated with a set of current kits, the number of cases is increasing exponentially.

This is a high time for molecular diagnostics companies and research facilities to re-strategizing their business decisions and develop future-fit strategies in this critical situation for meeting the current unmet demand for quality COVID-19 detection kits. Ingenious e-Brain calls molecular diagnostics leaders such as Agilent technologies to enter in the field of COVID -19 diagnostics by strategic collaboration with other existing players in the domain.